Interestingly, analysis of 60 patients with advanced pancreatic cancer who received gemcitabine showed that the serum levels of IL1β and IL6 were poor prognostic factors for overall survival and the levels of these cytokines predicted the efficacy of gemcitabine in this population (7). This evidence concerns the gene IL1B and pancreatic neoplasm.